Trial NCT04438382

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work
in treating patients with pneumonitis that does not respond to steroid treatment.
Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's
immune system and may interfere with the ability of tumor cells to grow and spread.
Intravenous immunoglobulin therapy may improve pneumonitis. It is not yet known whether
giving infliximab and intravenous immunoglobulin therapy will work better in treating
patients with pneumonitis.

Intervention

Infliximab, Intravenous Immunoglobulin Therapy, Prednisone, Quality-of-Life Assessment, Questionnaire Administration

Condition

Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis

Investigators

Jarushka Naidoo, Sheetal M. Kircher, Julie R. Brahmer, Kathleen J. Yost, Jason Beattie, Christopher Manley, Andrew Poklepovic

See list of participating sites